HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by John, E. Articles by Epstein, A.L. Search for Related Content PubMed PubMed Citation Articles by John, E. Articles by Epstein, A.L.

Technetium-99m-Labeled Monoclonal Antibodies: Influence of Technetium-99m Binding Sites

Department of Radiation Oncology and Nuclear Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints contact: M.L. Thakur PhD, Dept. of Radiation Oncology and Nuclear Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107.

ABSTRACT

A number of ^99mTc-labeled monoclonal antibodies (Mabs) are being evaluated for diagnostic applications. Preparations are carried out using both direct and indirect(bifunctional chelating agent, BFCA) labeling procedures in which nonspecific ^99mTc binding has been postulated. Methods: By using the ascorbic acid (AA) reduction mediated direct labeling procedure and diaminotetrathiol (N₂S₄) as a BFCA method, we examined the role of specific binding sites and aliphatic E amino groups of lysine as nonspecific binding sites for ^99mTc. Results: Labeling yields for the direct and N₂S₄ "regular" preparations averaged 73% ± 2.8% and 91% ± 2%, for the "specific" preparations, 60% ± 3.5% and 75% ± 2% and for the "nonspecific" preparations 13% ± 1.0% and 16% ± 1% respectively. All preparations were evaluated in tumor-bearing mice. The control and specific preparations permitted excellent scintigraphic visualization of tumors; the percentages of specific preparations in the tumors being 2.1% ± 0.5% and 3.1% ± 0.4%, respectively. With nonspecific preparations, tumors were not visualized and the percentages of administered radioactivity per gram of tumor were only 0.9% ± 0.2% and 0.9% ± 0.3%, respectively. Conclusions: In these ^99mTc labeling procedures, the amino group-mediated nonspecific binding of ^99mTc to Mabs can be as high as 16% and contributes to increased liver uptake and decreased tumor uptake of radioactivity.

Key Words: technetium-99m-labeled monoclonal antibodies • technetium-99m binding sites • FITC blocking • iodoacetate blocking